These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 11304529)
21. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. Pluda JM; Shay LE; Foli A; Tannenbaum S; Cohen PJ; Goldspiel BR; Adamo D; Cooper MR; Broder S; Yarchoan R J Natl Cancer Inst; 1993 Oct; 85(19):1585-92. PubMed ID: 7692072 [TBL] [Abstract][Full Text] [Related]
22. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. Chang HC; Samaniego F; Nair BC; Buonaguro L; Ensoli B AIDS; 1997 Oct; 11(12):1421-31. PubMed ID: 9342064 [TBL] [Abstract][Full Text] [Related]
23. Interaction of the transactivating protein HIV-1 tat with sulphated polysaccharides. Watson K; Gooderham NJ; Davies DS; Edwards RJ Biochem Pharmacol; 1999 Apr; 57(7):775-83. PubMed ID: 10075083 [TBL] [Abstract][Full Text] [Related]
24. Sodium pentosan polysulfate (PPS), an anti-HIV agent also exhibits synergism with AZT, lymphoproliferative activity, and virus enhancement. Anand R; Nayyar S; Galvin TA; Merril CR; Bigelow LB AIDS Res Hum Retroviruses; 1990 May; 6(5):679-89. PubMed ID: 1694454 [TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor. Jeang KT; Chun R; Lin NH; Gatignol A; Glabe CG; Fan H J Virol; 1993 Oct; 67(10):6224-33. PubMed ID: 7690421 [TBL] [Abstract][Full Text] [Related]
26. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat. Yang L; Morris GF; Lockyer JM; Lu M; Wang Z; Morris CB Virology; 1997 Aug; 235(1):48-64. PubMed ID: 9300036 [TBL] [Abstract][Full Text] [Related]
28. Discoveries of Tat-TAR interaction inhibitors for HIV-1. Yang M Curr Drug Targets Infect Disord; 2005 Dec; 5(4):433-44. PubMed ID: 16535863 [TBL] [Abstract][Full Text] [Related]
29. Wild-type and transactivation-defective mutants of human immunodeficiency virus type 1 Tat protein bind human TATA-binding protein in vitro. Wang Z; Morris GF; Rice AP; Xiong W; Morris CB J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):128-38. PubMed ID: 8680883 [TBL] [Abstract][Full Text] [Related]
30. Isolation of a cellular protein that binds to the human immunodeficiency virus Tat protein and can potentiate transactivation of the viral promoter. Desai K; Loewenstein PM; Green M Proc Natl Acad Sci U S A; 1991 Oct; 88(20):8875-9. PubMed ID: 1924346 [TBL] [Abstract][Full Text] [Related]
31. Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site. Schafer SL; Vlach J; Pitha PM J Virol; 1996 Oct; 70(10):6937-46. PubMed ID: 8794337 [TBL] [Abstract][Full Text] [Related]
32. HIV-1 regulatory protein tat induces RNA binding proteins in central nervous system cells that associate with the viral trans-acting-response regulatory motif. Kundu M; Ansari SA; Chepenik LG; Pomerantz RJ; Khalili K; Rappaport J; Amini S J Hum Virol; 1999; 2(2):72-80. PubMed ID: 10225209 [TBL] [Abstract][Full Text] [Related]
33. Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation. Kolson DL; Collman R; Hrin R; Balliet JW; Laughlin M; McGann KA; Debouck C; Gonzalez-Scarano F J Gen Virol; 1994 Aug; 75 ( Pt 8)():1927-34. PubMed ID: 8046394 [TBL] [Abstract][Full Text] [Related]
34. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. Gutheil WG; Subramanyam M; Flentke GR; Sanford DG; Munoz E; Huber BT; Bachovchin WW Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6594-8. PubMed ID: 7912830 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of Tat transactivation by the RNA polymerase II CTD-phosphatase FCP1. Licciardo P; Napolitano G; Majello B; Lania L AIDS; 2001 Feb; 15(3):301-7. PubMed ID: 11273209 [TBL] [Abstract][Full Text] [Related]
36. A quantitative GFP-based bioassay for the detection of HIV-1 Tat transactivation inhibitors. Daelemans D; De Clercq E; Vandamme AM J Virol Methods; 2001 Aug; 96(2):183-8. PubMed ID: 11445148 [TBL] [Abstract][Full Text] [Related]
37. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. Albini A; Fontanini G; Masiello L; Tacchetti C; Bigini D; Luzzi P; Noonan DM; Stetler-Stevenson WG AIDS; 1994 Sep; 8(9):1237-44. PubMed ID: 7528513 [TBL] [Abstract][Full Text] [Related]
38. Effect of HIV type 1 Tat protein on butyric acid-induced differentiation in a hematopoietic progenitor cell line. Mondal D; Agrawal KC AIDS Res Hum Retroviruses; 1996 Nov; 12(16):1529-36. PubMed ID: 8911578 [TBL] [Abstract][Full Text] [Related]
39. An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently Tat-transfected cells and required for optimal HIV-1 LTR transactivating activity. Zauli G; La Placa M; Vignoli M; Re MC; Gibellini D; Furlini G; Milani D; Marchisio M; Mazzoni M; Capitani S J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):306-16. PubMed ID: 7552492 [TBL] [Abstract][Full Text] [Related]
40. Translational effects of peptide antagonists of Tat protein of human immunodeficiency virus type 1. Choudhury I; Wang J; Stein S; Rabson A; Leibowitz MJ J Gen Virol; 1999 Mar; 80 ( Pt 3)():777-782. PubMed ID: 10092019 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]